· AIM:Toevaluatecentralmacularthickness(CMT)and meanchoroidalthickness (MCT)ineyeswithbranch retinal vein occlusion (BRVO), before and after ranibizumabtreatmentusingspectraldomain-optical coherencetomography(SD-OCT).
· METHODS:Forty-twopatientswithunilateralBRVO andmacularedemawereincludedinthisstudy.There were25menand17women.UsingSD-OCT,choroidal thicknesswasmeasuredat500 滋mintervalsupto1500 滋mtemporalandnasaltothefovea.MCTwascalculated basedontheaverageofthe7locations.Alltheeyes withBRVOweretreatedwithintravitrealranibizumab (0.5mg/0.05mL).ComparisonsbetweentheBRVOand felloweyeswereanalyzedusingMann-Whitney test.Preinjectionandpost-injectionmeasurementswereanalyzed usingWilcoxontestandrepeatedmeasureanalysis.
· RESULTS: At baseline, there was a significant differencebetweentheBRVOandfelloweyesinMCT 滋m,felloweyes229(157-327) 滋m] andCMT 滋m,felloweyes235 (148-378) 滋m (P=0.041,0.0001,respectively)].Following treatment, ) 滋m]andMCT [229(157-329) 滋m] decreased significantly compared to the baselinemeasurements ( =0.001,0.006,respectively). AlsoBCVA(logMAR)improvedsignificantly( =0.0001)in theBRVOeyesfollowingtreatment. [1] . VenousthrombusformationasaresultofRVOandleadsto poorvenousdrainage,dilationandtortuosityofthelarge retinalveinsandincreasedretinalcapillarypressure.These changesresultinexudationofblood,fluid,lipidintoretina, leadingtomacularedema [2] .Macularedemaisafrequent causeofvisuallossthatshouldbethemaintreatmenttarget [3] . Treatmentstrategiesformacularedemaconsistoffocallaser photocoagulation [4] [5] ,intravitrealsteroids [6] ,andinjectionof anti-vascularendothelialgrowthfactor(VEGF)protein compounds [7] [8] .MacularedemainpatientswithRVOseems tobecloselyrelatedtoVEGFlevelsinthevitreous [9] [10] .Thus, inhibitingVEGFseemstobeareasonabletherapeutic approach [8, 11] . Thechoroidisahighlyvasculartissuethatisdirectly influencedbyintraocularpressureaswellasperfusion pressure [12] .Choroidalbloodflowisthehighestofanytissue inthebodytosatisfythenormalmetabolicdemandsofthe outerretina [13] .RVOisaccompaniedwithretinalhypoxia whichleadstoincreasedVEGFexpressionintheretinal pigmentepithelium,pericytesandmicrovascularendothelial cells [14] .VEGFinducesvesseldilatationandincreasedocular bloodflowthroughamechanisminvolvingnitricoxide production,andisproposedtoincreasethechoroidal thickness [15] . [17] [18] ,laserDopplerflowmetry [19] andultrasound [20] .Although,itispossibletodiagnosechoroid vesselabnormalitiesandchangesinthebloodflowwiththese techniques,SD-OCTenabledustoachieve3-dimensional anatomicinformationaboutRPEandchoroidlayers [21] [22] . OCTisanoninvasiveimagingmodalityusedtoacquire high-resolutioncrosssectionalscansoftheretina.Recently, Spaide [21] describedanewacquisitiontechnique, namelyenhanceddepthimaging(EDI),usingSpectralisOCT device (HeidelbergEngineering,Heidelberg,Germany). Herein,placingtheacquiredstructuresdeeperclosetozero delay,allowedabettervisualizationofthechoroid [21] . DuetoincreasedinterestinchoroidalimagingwithOCT, othermethodshavebeenusedtotrytobettervisualizeand andmeasurethechoroid,includinguseofswept-source OCT [23] andlongerwavelengthOCT [24] [25] .Allofthese methods, however, potentiallycauselossofclear visualizationoftheretinalsurfacewhereotherpathologies suchasvitreo-maculartractionorepiretinalmembranemight bepresentandcontributingtopoorvision [26] . Ahighreliabilityandreproducibilityofchoroidalthickness measurementsacrossthreeSD-OCTsystems (Cirrus Spectralis,Cirrus RTVue,Spectralis RTVue)innormal subjects [16] .Twenty-eightsubjectsofyounghealthyadults withnoretinalandchoroidalpathologyandnormalvision wereanalyzed.Choroidalthicknessinnormaleyeswas manuallymeasuredin5areas.Measurementsfromanypair ofthreeinstrumentswerestronglycorrelated.Therewas goodreproducibilitybetweenchoroidalthicknessofimages acquiredbyCirrus,SpectralisandRTVue [16] . InRTVuesoftware"chorioretinal"modeachievesthesame purposeasEDIdescribedbySpaide [21] withaslightly differentapproach.RTVue's'chorioretinal'modemovesthe zerodelayclosertothechoroidandachievesthesameeffect asEDIwithoutinvertingtheretinalimage [27] .Usingthis technique,wefoundthateyeswithBRVOshowed significantlygreaterMCTandCMTcomparedtothefellow controleyesbeforethetreatment(zerovisit).Atthe follow-upvisit(onemonthfollowingthethirdinjection) CMTandMCTvaluesimprovedintheBRVOeyes comparedtothezerovisitmeasurements.Inthecontroleyes, however,nodifferenceinCMTandMCTbetweenzeroand follow-upvisitwasfound.Thiscouldbeexplainedby increasedexpressionofVEGFleadingtoincreasedthickness ofchoroidinpatientswithBRVO.
Severalstudiesfocusedonchoroidalthicknessmeasurements invariousdiseasesoftheretinaandchoroidsuchas
Vogt-Koyanagi-Haradadisease [28] ,polypoidalchoroidal vasculopathy [29] andcentralserouschorioretinopathy [30] .It wasdemonstratedthatchoroidalthicknesscanbemeasured bySD-OCT,andchoroidalthicknessdisparityexistsamong patientswiththeclinicaldiagnosisofwetanddryage-related maculardegeneration [12] .Imamura [30] 
